Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus
NCT06280703Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3938577 in type 1 diabetes mellitus (T1D) (10 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with one or more Adverse Events and Serious Adverse Events at 11 weeks, Number of Participants With Clinically Significant Changes in Vital Signs at 11 weeks and 3 more. Started May 2024; status: completed.
02
Drugs
LY3938577
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06280703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280703.